Acorda Therapeutics | ACOR

Acorda Therapeutics traded at $0.45 this Monday August 8th, increasing $0.002 or 0.54 percent since the previous trading session. Looking back, over the last four weeks, Acorda Therapeutics gained 2.63 percent. Over the last 12 months, its price fell by 87.78 percent. Looking ahead, we forecast Acorda Therapeutics to be priced at 0.43 by the end of this quarter and at 0.40 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 16.62 0.18 1.09% -13.26%
Acorda Therapeutics 0.45 0.002 0.54% -87.78%
Agios Pharmaceuticals 29.38 -0.36 -1.21% -34.91%
ALKERMES 25.64 -0.11 -0.43% -10.29%
Amgen 247.67 0.38 0.15% 8.65%
Anika Therapeutics 23.46 0.78 3.44% -42.32%
Aptinyx Inc 0.59 0.08 14.80% -77.09%
Arrowhead Research 47.02 1.06 2.31% -25.10%
Biogen 214.29 -3.27 -1.50% -36.45%
BioMarin Pharmaceutical 95.70 -0.12 -0.13% 23.48%
Cara Therapeutics 11.50 0.23 2.04% -8.07%
Clovis Oncology 1.45 -0.21 -12.65% -70.53%
Cytokinetics 53.54 1.72 3.32% 67.89%
Enanta Pharmaceuticals 71.82 0.55 0.77% 59.25%
Gilead Sciences 61.50 -0.10 -0.16% -11.18%
GlaxoSmithKline 1,647.20 -12.20 -0.74% 13.91%
Halozyme Therapeutics 44.60 -0.44 -0.98% 10.29%
Heron Therapeutics 3.79 0.22 6.16% -68.26%
Insmed 27.87 -0.08 -0.29% 13.29%
Ligand Pharmaceuticals 103.22 3.97 4.00% -6.10%
MannKind 4.30 -0.05 -1.15% 8.04%
Merck 184.95 -1.15 -0.62% -0.56%
Moderna Inc 171.39 -11.55 -6.31% -62.48%
Neurocrine Biosciences 107.68 3.09 2.95% 21.14%
Novartis 82.96 0.68 0.83% -2.18%
Pfizer 49.71 0.14 0.28% 3.15%
Ultragenyx Pharmaceutical 51.79 -0.85 -1.61% -42.45%
Sanofi 95.42 -1.43 -1.48% 10.22%
Teva Pharmaceutical Industries Ltd 3,688.00 71.00 1.96% 13.69%
Vertex Pharmaceuticals 298.11 4.16 1.42% 51.74%

Indexes Price Day Year
USND 12498 -146.80 -1.16% -15.49%

Acorda Therapeutics
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. Its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation is used in the development of variety of inhaled medicines. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). It markets Inbrija for intermittent treatment of off episodes, also known as off periods, in people with Parkinson's disease treated with carbidopa/levodopa. Ampyra is a drug to improve walking in adults with multiple sclerosis. Its product pipelines includes ARCUS for acute migraine, Cimaglermin alfa for heart failure and rHIgM22 for multiple sclerosis.